First Mercantile Trust Co. Sells 10,849 Shares of McKesson Co. (MCK)
First Mercantile Trust Co. cut its position in McKesson Co. (NYSE:MCK) by 93.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 770 shares of the company’s stock after selling 10,849 shares during the quarter. First Mercantile Trust Co.’s holdings in McKesson were worth $102,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MCK. Fort L.P. acquired a new position in McKesson in the 2nd quarter valued at $110,000. Flagship Harbor Advisors LLC acquired a new position in McKesson in the 2nd quarter valued at $118,000. Reilly Financial Advisors LLC raised its holdings in McKesson by 506.8% in the 3rd quarter. Reilly Financial Advisors LLC now owns 898 shares of the company’s stock valued at $119,000 after acquiring an additional 750 shares in the last quarter. Bray Capital Advisors acquired a new position in McKesson in the 3rd quarter valued at $123,000. Finally, FNY Investment Advisers LLC raised its holdings in McKesson by 88.6% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,120 shares of the company’s stock valued at $148,000 after acquiring an additional 526 shares in the last quarter. Institutional investors and hedge funds own 89.97% of the company’s stock.
McKesson stock opened at $126.19 on Tuesday. The company has a quick ratio of 0.56, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. McKesson Co. has a 52 week low of $117.19 and a 52 week high of $178.86. The firm has a market cap of $24.21 billion, a PE ratio of 10.00, a price-to-earnings-growth ratio of 1.41 and a beta of 1.05.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 2nd. Stockholders of record on Monday, December 3rd will be issued a dividend of $0.39 per share. The ex-dividend date is Friday, November 30th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 1.24%. McKesson’s dividend payout ratio (DPR) is currently 12.36%.
In other news, Director N Anthony Coles sold 1,350 shares of the business’s stock in a transaction on Friday, August 31st. The stock was sold at an average price of $128.69, for a total transaction of $173,731.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.87% of the stock is currently owned by insiders.
Several equities analysts have weighed in on MCK shares. Barclays dropped their price objective on McKesson from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Friday, October 26th. Royal Bank of Canada set a $155.00 price objective on McKesson and gave the company a “hold” rating in a report on Friday, October 26th. JPMorgan Chase & Co. dropped their price objective on McKesson from $181.00 to $160.00 and set an “overweight” rating for the company in a report on Friday, July 27th. ValuEngine raised McKesson from a “strong sell” rating to a “sell” rating in a report on Monday, October 29th. Finally, Mizuho reaffirmed a “hold” rating and issued a $133.00 price objective on shares of McKesson in a report on Sunday, August 12th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company’s stock. McKesson currently has a consensus rating of “Hold” and a consensus price target of $150.26.
WARNING: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/11/20/first-mercantile-trust-co-sells-10849-shares-of-mckesson-co-mck.html.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Featured Article: No Load Funds
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.